Cost-Utility Analysis of Biologic Treatments for Moderate-to-Severe Crohn's Disease

Study Objective To compare the cost versus utility of four guideline‐recommended biologic treatments—infliximab, adalimumab, certolizumab pegol, and natalizumab—for the treatment of Crohn's disease from a United States payer perspective. Design Cost‐utility decision analytic model using a Monte Carlo simulation of 10,000 cases. Data Source Published primary and tertiary literature. Patients Patients with moderate‐to‐severe Crohn's disease, as...